Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML (NCT07508982)

🧪 Interventions in This Study

• Azacitidine (DRUG)
• APG1252 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (1 Sites)

• UT MD Anderson — Houston, Texas

📞 Contact the Study Coordinator

Phone: (713) 563-3534

Email: tkadia@mdanderson.org

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in AML

• ALLG AMLM26 INTERCEPT (Investigating Novel Therapy to Target Early Relapse and Clonal Evolution as Pre-emptive Therapy in AML): A Multi-arm, Precision-based, Recursive, Platform Trial — Houston, Texas
• A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant — Rochester, New York
• A Long Term Follow-up Study of TScan TCR-T Products — Duarte, California
• CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF) — Sacramento, California
• Cardioprotection in AML — Charlottesville, Virginia
• UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy — Birmingham, Alabama

Explore by condition: All AML clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.